Acorda Therapeutics
| Company type | Public |
|---|---|
| Industry | |
| Founded | 1995 |
| Founder | Ron Cohen |
| Headquarters | 420 Saw Mill River Road, Ardsley, New York, United States |
Key people | Ron Cohen (CEO) |
| Products | |
| Revenue | US$192.408 million (2019) |
| US$−311.632 million (2019) | |
| US$−272.966 million (2019) | |
| Total assets | US$799.718 million (2019) |
| Total equity | US$310.820 million (2019) |
Number of employees | 344 (2020) |
| Website | acorda |
Acorda Therapeutics, Inc. is an American biotechnology company based in Pearl River, New York. The company develops therapies that improve neurological function in people with Parkinson's disease, multiple sclerosis and other neurological disorders. Acorda Therapeutics manufactures and markets the drugs Inbrija (levodopa inhalation powder) and Ampyra (dalfampridine) in the United States.